Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment Optimization for Patients With Chronic Myeloid Leukemia (CML) With Treatment naïve Disease (1st Line) and Patients With Resistance or Intolerance Against Alternative Abl-Kinase Inhibitors (≥2nd Line)

NCT02890784 is registered in ClinicalTrials.gov with University of Jena as lead sponsor.

NCT NCT02890784
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02890784 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment Optimization for Patients With Chronic Myeloid Leukemia (CML) With Treatment naïve Disease (1st Line) and Patients With Resistance or Intolerance Against Alternative Abl-Kinase Inhibitors (≥2nd Line)
Lead sponsor
University of Jena
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2016
Completion date
March 31, 2023
Enrollment
291 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

myeloid leukemia, chronic